title: Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity.
abstract: M30 and M65 are ELISAs that detect different circulating forms of cytokeratin 18. Using the aurora kinase inhibitor AZD1152 and the SW620 human colon cancer xenograft, experiments were conducted to qualify preclinically both assays as serologic biomarkers of cell death. Using two different apoptotic markers, the kinetics of cell death induced by AZD1152 was first characterized in vitro in three different cell lines and shown to peak 5 to 7 days after drug addition. Treatment of non-tumor-bearing rats with AZD1152 (25 mg/kg) produced no alterations in circulating baseline values of M30 and M65 antigens. In treated, tumor-bearing animals, M30 detected a 2- to 3-fold (P < 0.05) increase in plasma antigen levels by day 5 compared with controls. This correlated to a 3-fold increase in the number of apoptotic cells detected on day 5 in SW620 xenografts using immunohistochemistry. By contrast, M65 did not detect a drug-induced increase in circulating antigen levels at day 5. However, M65 plasma levels correlated to changes in tumor growth in control animals (r(2) = 0.93; P < 0.01) and also followed the magnitude of the temporal effect of AZD1152 on tumor growth. An intermediate but active dose of AZD1152 (12.5 mg/kg) produced a less significant increase in M30 plasma levels at day 5. It was also confirmed that the plasma profiles of M30 and M65 mirrored closely those measured in whole tumor lysates. We conclude that M30 is a pharmacodynamic biomarker of AZD1152-induced apoptosis in the SW620 xenograft model, whereas M65 is a biomarker of therapeutic response.
authors.affiliation: Clinical and Experimental Pharmacology, Paterson Institute for Cancer Research, University of Manchester, Manchester, UK. jcummings@picr.man.ac.uk
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Cummings
authors.forename: Cassandra
authors.initials: C
authors.lastname: Hodgkinson
authors.forename: Rajesh
authors.initials: R
authors.lastname: Odedra
authors.forename: Patrizia
authors.initials: P
authors.lastname: Sini
authors.forename: Simon P
authors.initials: SP
authors.lastname: Heaton
authors.forename: Kirsten E
authors.initials: KE
authors.lastname: Mundt
authors.forename: Tim H
authors.initials: TH
authors.lastname: Ward
authors.forename: Robert W
authors.initials: RW
authors.lastname: Wilkinson
authors.forename: Jim
authors.initials: J
authors.lastname: Growcott
authors.forename: Andrew
authors.initials: A
authors.lastname: Hughes
authors.forename: Caroline
authors.initials: C
authors.lastname: Dive
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D014408:Biomarkers, Tumor / Q000097:blood*; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods*; D053538:Keratin-18 / Q000097:blood*; D008297:Male; D009374:Neoplasms, Experimental / Q000473:pathology*; D010755:Organophosphates / Q000494:pharmacology*; D011799:Quinazolines / Q000494:pharmacology*; D051381:Rats; D011923:Rats, Nude
chemical_list: C520647:2-((3-((4-((5-(2-((3-fluorophenyl)amino)-2-oxoethyl)-1H-pyrazol-3-yl)amino)quinazolin-7-yl)oxy)propyl)(ethyl)amino)ethyl dihydrogen phosphate; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D053538:Keratin-18; D010755:Organophosphates; D011799:Quinazolines